Effect of Pea Flour in Bread on Blood Glucose

January 4, 2023 updated by: St. Boniface Hospital

A Randomized, Controlled, Cross-over Trial Examining the Effect of Yellow Pea Flour in Bread on Post-prandial Glycaemic Response in Healthy Adults

This study's overall goal is to investigate methods to improve the acceptability of pulse containing foods that provide a health benefit to consumers. The health benefits we are testing are post-prandial blood glucose attenuation and appetite related sensations in healthy human volunteers.

Study Overview

Detailed Description

A randomized, controlled, cross-over study designed to examine the post-prandial glycaemic response, metabolism of bioactives and appetite related sensations to 20% incorporation of yellow pea flour (untreated, heat treated with 0% moisture and heat treated with 10% moisture) into bread will be conducted at the I.H. Asper Clinical Research Institute in Winnipeg, Manitoba. Eligible participants who have provided consent will be asked to attend 4 clinic visits in a fasted state. Participants will be given bread containing 20% yellow pea flour at 3 visits and bread with 100% wheat flour at 1 visit. At each visit participants will provide 7 venous blood samples via indwelling catheter, 7 capillary blood samples via finger poke, 2 urine samples, 5 questionnaires about their appetite and a questionnaire about the acceptability of the products. Each visit will last approximately 3h and be separated by 3-14 days.

Study Type

Interventional

Enrollment (Actual)

24

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Manitoba
      • Winnipeg, Manitoba, Canada, R2H 2A6
        • I. H. Asper Clinical Research Institute

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 40 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. Generally healthy male or female, between the age of 18-40 years;
  2. Body mass index (BMI) 18.5-30.0 kg/m2;
  3. Habitually consume breakfast, lunch and dinner in the morning, mid-day and evening, respectively;
  4. Willing to provide informed consent;
  5. Willing/able to comply with the requirements of the study.

Exclusion Criteria:

  1. Pregnant or lactating;
  2. Medical history of diabetes mellitus, fasting blood glucose ≥6.1 mmol/L, HbA1c ≥6.0%, or use of insulin or oral medication to control blood sugar;
  3. Medical history of cardiovascular disease;
  4. Systolic blood pressure >140 mmHg or diastolic blood pressure >90 mmHg;
  5. Fasting plasma total cholesterol >7.8 mmol/L;
  6. Fasting plasma HDL <0.9 mmol/L;
  7. Fasting plasma LDL >5.0 mmol/L;
  8. Fasting plasma triglycerides >2.3 mmol/L;
  9. Major surgery within the last 3 months;
  10. Medical history of inflammatory disease (ie. Systemic lupus erythematosis, rheumatoid arthritis, psoriasis) or use of any corticosteroid medications within 3 months;
  11. Medical history of liver disease or liver dysfunction (defined as plasma aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≥3 times the upper limit of normal (ULN));
  12. Medical history of kidney disease or kidney dysfunction (defined as blood urea nitrogen and creatinine ≥3 times the ULN));
  13. Presence of a gastrointestinal disorder, daily use of any stomach acid-lowering medications or laxatives (including fibre supplements) within the past month or antibiotic use within the past 6 weeks;
  14. Active treatment for any type of cancer within 1 year prior to study start;
  15. Shift worker (a system of employment where an individual's normal hours of work are in part, outside the period of normal working day; 6am and 8pm);
  16. Smoking, use of tobacco or a nicotine replacement product, and cannabis in any form (within the last 3 months);
  17. Allergies to peas or wheat;
  18. Aversion or unwillingness to eat study foods;
  19. Consuming >4 servings of pulses per week;
  20. Use of any prescription or non-prescription drug, herbal or nutritional supplement known to affect glycaemia or appetite;
  21. Participation in another clinical trial, current or in the past 4 weeks;
  22. Unstable body weight (defined as >5% change in 3 months) or actively participating in a weight loss program.
  23. Other medical, psychiatric, or behavioral factors that in the judgment of the principal Investigator may interfere with study participation or the ability to follow the intervention protocol;

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Untreated
Bread containing 20% yellow pea flour.
Bread made with 20% yellow pea flour that was untreated.
Experimental: Heat treated with 0% moisture
Bread containing 20% yellow pea flour.
Bread made with 20% yellow pea flour that was heat treated with 0% moisture.
Experimental: Heat treated with 10% moisture
Bread containing 20% yellow pea flour.
Bread made with 20% yellow pea flour that was heat treated with 10% moisture.
Active Comparator: Wheat
Bread made with 100% wheat flour
Bread made with 100% wheat

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Post-prandial glucose
Time Frame: 120 minutes
incremental area under the curve (iAUC) for glucose
120 minutes
Post-prandial insulin
Time Frame: 120 minutes
iAUC insulin
120 minutes

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Urinary metabolite profile
Time Frame: 120 minutes
Concentration of metabolites in urine
120 minutes
Plasma metabolite profile
Time Frame: 120 minutes
Concentration of metabolites in plasma
120 minutes

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Hunger
Time Frame: 120 minutes
Area under the curve (AUC) using visual analog scales
120 minutes
Fullness
Time Frame: 120 minutes
AUC using visual analog scales
120 minutes
Desire to eat
Time Frame: 120 minutes
AUC using visual analog scales
120 minutes
Prospective consumption
Time Frame: 120 minutes
AUC using visual analog scales
120 minutes
Acceptability of test products
Time Frame: 15 minutes
Ratings of color, aroma, flavor, texture and frequency of eating
15 minutes
Gastrointestinal effects
Time Frame: 24 hours
Incidence of gastrointestinal side effects
24 hours

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Heather Blewett, PhD, Agriculture and Agri-Food Canada

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 17, 2019

Primary Completion (Actual)

December 18, 2019

Study Completion (Actual)

December 18, 2019

Study Registration Dates

First Submitted

April 13, 2018

First Submitted That Met QC Criteria

April 13, 2018

First Posted (Actual)

April 24, 2018

Study Record Updates

Last Update Posted (Estimate)

January 6, 2023

Last Update Submitted That Met QC Criteria

January 4, 2023

Last Verified

July 1, 2021

More Information

Terms related to this study

Other Study ID Numbers

  • HS21603 (B2018:026)
  • RRC/2018/1748 (Other Identifier: St. Boniface Hopsital Research Review Committee)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

Yes

IPD Plan Description

All IPD that underlie results in a publication.

IPD Sharing Time Frame

From the time the data is collected until manuscript is accepted for publication.

IPD Sharing Access Criteria

Michel Aliani and Sora Ludwig will have access to data necessary for manuscript preparation.

IPD Sharing Supporting Information Type

  • Study Protocol
  • Statistical Analysis Plan (SAP)
  • Informed Consent Form (ICF)
  • Clinical Study Report (CSR)
  • Analytic Code

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Post-prandial Glycaemic Response

Clinical Trials on Untreated

3
Subscribe